FCC Certifies Comsearch AFC for Commercial Deployment
Comsearch AFC extends the full range of 6 GHz capabilities to unlicensed standard power devices to support a broad range of unlicensed deployments including Wi-Fi... Read more.
Dock Health Achieves HITRUST Essentials, 1-year (e1) Certification Demonstrating Foundational Cybersecurity
HITRUST Essentials, 1-year (e1) Certification validates Dock Health is committed to foundational cybersecurity controls and information risk management. GREAT BARRINGTON,... Read more.
WNS and HFS Research Launch Gen AI Market Impact Report
NEW YORK, LONDON & MUMBAI–(BUSINESS WIRE)–$WNS #AI–WNS (Holdings) Limited (NYSE: WNS), a leading provider of global Business Process Management... Read more.
Klaviyo Launches Klaviyo AI
Unlock smarter marketing with AI-powered automation BOSTON–(BUSINESS WIRE)–Klaviyo (NYSE: KVYO), the company that powers smarter digital relationships,... Read more.
Bicara Therapeutics to Participate in Upcoming March Investor Conferences
BOSTON–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune... Read more.
Barclays and Blackstone Credit & Insurance Agree to Sale of Credit Card Receivables
LONDON & NEW YORK–(BUSINESS WIRE)–Barclays PLC (“Barclays”) and Blackstone Credit & Insurance (“Blackstone”) today announced... Read more.
SimpleClosure Announces $4M Seed and 14x Growth Post-Launch
Fresh funding for the automated business-closure platform comes just months after pre-seed round SANTA MONICA, Calif.–(BUSINESS WIRE)–SimpleClosure,... Read more.
Roy Rogers Restaurants Introduces Refranchising Program
Current Multi-Unit Franchisee Purchased 6th Roy Rogers Location to Kick-off Program FREDERICK, Md.–(BUSINESS WIRE)–Roy Rogers Restaurants® is introducing... Read more.
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
FDA grants Priority Review with target action date of June 28, 2024 Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful... Read more.
Nuveen Churchill Direct Lending Corp. Announces Fourth Quarter and Full Year 2023 Results
NEW YORK–(BUSINESS WIRE)–Nuveen Churchill Direct Lending Corp. (NYSE: NCDL) (“NCDL” or “the Company”), a business development company externally... Read more.